EASD 2025 15 - 19 September 2025

Improved treatment satisfaction with once-weekly IcoSema vs daily basal-bolus therapy in adults with type 2 diabetes inadequately controlled on daily basal insulin (COMBINE 3)

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress short oral presentation

Insulin

IcoSema (Icodec Semaglutide)

PHASE 3 (RCT)

Are you a healthcare professional?